- Home
- SBSI vs KPTI Comparison
SBSI vs KPTI Comparison
Compare SBSI & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBSI
- KPTI
- Stock Information
- Founded
- SBSI 1960
- KPTI 2008
- Country
- SBSI United States
- KPTI United States
- Employees
- SBSI N/A
- KPTI N/A
- Industry
- SBSI Major Banks
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- SBSI Finance
- KPTI Health Care
- Exchange
- SBSI Nasdaq
- KPTI Nasdaq
- Market Cap
- SBSI 861.5M
- KPTI 54.4M
- IPO Year
- SBSI N/A
- KPTI 2013
- Fundamental
- Price
- SBSI $28.89
- KPTI $6.15
- Analyst Decision
- SBSI Hold
- KPTI Strong Buy
- Analyst Count
- SBSI 2
- KPTI 5
- Target Price
- SBSI $37.00
- KPTI $61.00
- AVG Volume (30 Days)
- SBSI 121.0K
- KPTI 84.2K
- Earning Date
- SBSI 04-29-2025
- KPTI 05-20-2025
- Dividend Yield
- SBSI 4.96%
- KPTI N/A
- EPS Growth
- SBSI 7.94
- KPTI N/A
- EPS
- SBSI 2.91
- KPTI N/A
- Revenue
- SBSI $254,817,000.00
- KPTI $145,237,000.00
- Revenue This Year
- SBSI $10.91
- KPTI $4.87
- Revenue Next Year
- SBSI $5.37
- KPTI $16.29
- P/E Ratio
- SBSI $9.98
- KPTI N/A
- Revenue Growth
- SBSI 6.49
- KPTI N/A
- 52 Week Low
- SBSI $25.30
- KPTI $3.51
- 52 Week High
- SBSI $38.00
- KPTI $18.00
- Technical
- Relative Strength Index (RSI)
- SBSI 56.97
- KPTI 52.82
- Support Level
- SBSI $28.21
- KPTI $5.52
- Resistance Level
- SBSI $28.74
- KPTI $7.90
- Average True Range (ATR)
- SBSI 0.62
- KPTI 0.67
- MACD
- SBSI 0.13
- KPTI 0.09
- Stochastic Oscillator
- SBSI 76.85
- KPTI 41.90
About SBSI Southside Bancshares Inc.
Southside Bancshares Inc is a bank holding company. Through its subsidiary, the Southside Bank, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.